Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867213 | 1.00 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3662232 | 1.00 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| Water SCHEMBL9027853 | 0.99 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| Water SCHEMBL9027861 | 0.99 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL27267985 | 0.89 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3266289 | 0.87 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4466593 | 0.85 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL783913 | 0.85 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL783912 | 0.85 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4466599 | 0.85 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1296659-A4 | PHARMACEUTICAL COMPOSITIONS OF 2'-DEOXY-2'-(FLUOROMETHYLENE)CYTIDINE | CHIRON CORP (US) | 2005-08-31 | — | — | EP | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1296659-A1 | PHARMACEUTICAL COMPOSITIONS OF 2'-DEOXY-2'-(FLUOROMETHYLENE)CYTIDINE | Matrix Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2001091731-A1 | PHARMACEUTICAL COMPOSITIONS OF 2'-DEOXY-2'-(FLUOROMETHYLENE)CYTIDINE | MATRIX PHARMACEUTICAL, INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-1996028170-A1 | REDUCED TOXICITY COMPOSITIONS AND METHODS FOR TREATING HIV INFECTIONS | YALE UNIVERSITY (US) | 1996-09-19 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4281068-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-5589587-A | Process for the preparation of ribonucleotide reductase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0738273-A1 | MONOHYDRATE OF (E)-2'-DEOXY-2'-(FLUOROMETHYLENE)CYTIDINE | MERRELL PHARMACEUTICALS INC. (US) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018815-A1 | MONOHYDRATE OF (E)-2'-DEOXY-2'-(FLUOROMETHYLENE)CYTIDINE | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0640092-A1 | A PROCESS FOR THE PREPARATION OF RIBONUCLEOTIDE REDUCTASE INHIBITORS. | MERRELL DOW PHARMA (US) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885THRB 4461/4885MTOR 531/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885THRB 3341/4885MTOR 131/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885THRB 3341/4885MTOR 131/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885THRB 3341/4885MTOR 131/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885THRB 3341/4885MTOR 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.